Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen ; volume:38 ; number:1 ; day:1 ; month:7 ; year:2023 ; pages:161-167 ; date:1.2024
Eye ; 38, Heft 1 (1.7.2023), 161-167, 1.2024
- Creator
-
Cozzi, Mariano
Monteduro, Davide
Esposito, Raffaele Antonio
Spooner, Kimberly L.
Fraser-Bell, Samantha
Staurenghi, Giovanni
Romano, Francesco
Airaldi, Matteo
Chang, Andrew A.
Invernizzi, Alessandro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41433-023-02652-3
- URN
-
urn:nbn:de:101:1-2024031814260439856809
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cozzi, Mariano
- Monteduro, Davide
- Esposito, Raffaele Antonio
- Spooner, Kimberly L.
- Fraser-Bell, Samantha
- Staurenghi, Giovanni
- Romano, Francesco
- Airaldi, Matteo
- Chang, Andrew A.
- Invernizzi, Alessandro
- SpringerLink (Online service)
Other Objects (12)
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Efficacy and Durability of Faricimab in Naïve Eyes with Neovascular Age-Related Macular Degeneration
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration
Second eyes to develop neovascular age-related macular degeneration have fewer symptoms and better one-year visual outcomes
Comparison of choriocapillary flow density between fellow eyes of polypoidal choroidal vasculopathy and neovascular age-related macular degeneration
Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration
XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
Near-infrared reflectance imaging of neovascular age-related macular degeneration